Diekman Brian O, Thakore Pratiksha I, O'Connor Shannon K, Willard Vincent P, Brunger Jonathan M, Christoforou Nicolas, Leong Kam W, Gersbach Charles A, Guilak Farshid
1 Department of Orthopaedic Surgery, Duke University Medical Center , Durham, North Carolina.
Tissue Eng Part A. 2015 Apr;21(7-8):1261-74. doi: 10.1089/ten.TEA.2014.0240. Epub 2015 Jan 23.
The limited regenerative capacity of articular cartilage contributes to progressive joint dysfunction associated with cartilage injury or osteoarthritis. Cartilage tissue engineering seeks to provide a biological substitute for repairing damaged or diseased cartilage, but requires a cell source with the capacity for extensive expansion without loss of chondrogenic potential. In this study, we hypothesized that decreased expression of the cell cycle inhibitor p21 would enhance the proliferative and chondrogenic potential of differentiated induced pluripotent stem cells (iPSCs). Murine iPSCs were directed to differentiate toward the chondrogenic lineage with an established protocol and then engineered to express a short hairpin RNA (shRNA) to reduce the expression of p21. Cells expressing the p21 shRNA demonstrated higher proliferative potential during monolayer expansion and increased synthesis of glycosaminoglycans (GAGs) in pellet cultures. Furthermore, these cells could be expanded ∼150-fold over three additional passages without a reduction in the subsequent production of GAGs, while control cells showed reduced potential for GAG synthesis with three additional passages. In pellets from extensively passaged cells, knockdown of p21 attenuated the sharp decrease in cell number that occurred in control cells, and immunohistochemical analysis showed that p21 knockdown limited the production of type I and type X collagen while maintaining synthesis of cartilage-specific type II collagen. These findings suggest that manipulating the cell cycle can augment the monolayer expansion and preserve the chondrogenic capacity of differentiated iPSCs, providing a strategy for enhancing iPSC-based cartilage tissue engineering.
关节软骨有限的再生能力会导致与软骨损伤或骨关节炎相关的进行性关节功能障碍。软骨组织工程旨在提供一种生物替代品来修复受损或患病的软骨,但需要一种能够大量扩增且不丧失软骨生成潜力的细胞来源。在本研究中,我们假设细胞周期抑制剂p21表达的降低会增强分化的诱导多能干细胞(iPSC)的增殖和软骨生成潜力。将小鼠iPSC按照既定方案定向分化为软骨细胞系,然后进行基因工程改造以表达短发夹RNA(shRNA)来降低p21的表达。表达p21 shRNA的细胞在单层扩增过程中表现出更高的增殖潜力,并且在微团培养中糖胺聚糖(GAG)的合成增加。此外,这些细胞在另外三次传代中可扩增约150倍,且随后GAG的产生没有减少,而对照细胞在另外三次传代后GAG合成潜力降低。在经过大量传代的细胞形成的微团中,p21的敲低减弱了对照细胞中出现的细胞数量急剧下降,免疫组织化学分析表明,p21敲低限制了I型和X型胶原蛋白的产生,同时维持了软骨特异性II型胶原蛋白的合成。这些发现表明,操纵细胞周期可以增强单层扩增并保留分化的iPSC的软骨生成能力,为增强基于iPSC的软骨组织工程提供了一种策略。